2020
DOI: 10.34172/ps.2019.62
|View full text |Cite
|
Sign up to set email alerts
|

Protective Effects of Ursodeoxycholic Acid on Valproic Acid Induced Hepatotoxicity in Epileptic Children with Recurrent Seizure; A Double-Blinded Randomized Clinical Trial

Abstract: Background : There are controversies regarding the protective role of ursodeoxycholic acid (UDCA) against valproic acid (VPA)-induced hepatotoxicity in children. In the present clinical trial, we assessed the potential role of UDCA in preventing VPA-induced fluctuations of hepatic enzymes in epileptic children with recurrent seizures. Methods: Two-hundred children with epileptic seizures were randomly allocated into either intervention (VPA+UDCA) or control (VPA+ placebo) group. Fluctuations of liv… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(2 citation statements)
references
References 44 publications
(51 reference statements)
0
2
0
Order By: Relevance
“…Presently, our patients are being treated with ursodeoxycholic acid, a secondary bile acid that regulates cholesterol levels by slowing down the rate of intestinal absorption of cholesterol and is used to treat various liver disorders such as cholestasis, non‐alcoholic steatohepatitis, non‐alcoholic fatty liver disease, intrahepatic cholestasis of pregnancy, primary biliary cirrhosis, hepatitis C virus infection, and hepatobiliary disorders in children. 23 There is no definitive treatment available for MAS yet. 10 Patients should be examined periodically and long term for all endocrine disorders by specialists.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Presently, our patients are being treated with ursodeoxycholic acid, a secondary bile acid that regulates cholesterol levels by slowing down the rate of intestinal absorption of cholesterol and is used to treat various liver disorders such as cholestasis, non‐alcoholic steatohepatitis, non‐alcoholic fatty liver disease, intrahepatic cholestasis of pregnancy, primary biliary cirrhosis, hepatitis C virus infection, and hepatobiliary disorders in children. 23 There is no definitive treatment available for MAS yet. 10 Patients should be examined periodically and long term for all endocrine disorders by specialists.…”
Section: Discussionmentioning
confidence: 99%
“…Despite the presence of abnormalities in liver function tests, the course of liver involvement in our patient has been benign so far, without progressive cirrhosis or liver failure. Presently, our patients are being treated with ursodeoxycholic acid, a secondary bile acid that regulates cholesterol levels by slowing down the rate of intestinal absorption of cholesterol and is used to treat various liver disorders such as cholestasis, non‐alcoholic steatohepatitis, non‐alcoholic fatty liver disease, intrahepatic cholestasis of pregnancy, primary biliary cirrhosis, hepatitis C virus infection, and hepatobiliary disorders in children 23 . There is no definitive treatment available for MAS yet 10 .…”
Section: Discussionmentioning
confidence: 99%